@article {5263,
	title = {A Randomized Trial of the Activity and Safety of Ro 24-7429 (Tat Antagonist) versus Nucleoside for Human Immunodeficiency Virus Infection},
	journal = {Journal of Infectious Diseases},
	volume = {172},
	year = {1995},
	month = {November 1, 1995},
	pages = {1246-1252},
	abstract = {Ro 24-7429, a Tat antagonist, dosed at 75, 150, or 300 mg/day, was compared with nucleoside analogue (zidovudine or didanosine) for 12 weeks in 96 human immunodeficiency virus (HIV)-infected patients to assess safety and activity. The primary adverse effect of Ro 24-7429 was rash, which necessitated treatment discontinuation in 6 of 71 patients. Nucleoside analogue treatment produced an average increase in CD4 cell count of 28 cells/mm3 at week 8 versus a decrease of 27 cells/mm3 in recipients of Ro 24-7429 (P < .001). Serum HIV p24 antigen levels decreased by an average of 111 pg/mL in nucleoside recipients at week 8 compared with an increase of 41 pg/mL in recipients of Ro 24-7429 (P = .007). Nucleoside-treated patients had a mean 0.66 log10 reduction in infectious peripheral blood mononuclear cells, while Ro 24-7429 recipients had a mean 0.02 log10 reduction (P = .02). No dose-response relationships were observed in the Ro 24-7429 groups. In this study, Ro 24-7429 treatment showed no evidence of antiviral activity.},
	doi = {10.1093/infdis/172.5.1246},
	url = {http://jid.oxfordjournals.org/content/172/5/1246.abstract},
	author = {Haubrich, Richard H. and Flexner, Charles and Lederman, Michael M. and Hirsch, Martin and Pettinelli, Carla P. and Ginsberg, Richard and Lietman, Paul and Hamzeh, Fayez M. and Spector, Stephen A. and Richman, Douglas D.}
}
